Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Frans A. E. Sollie"'
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 43:282-293
Objective: A novel sulfonamide derivative, S-3304, was discovered as a potent matrix metalloproteinase (MMP) inhibitor. It is a more specific inhibitor to MMP-2 and MMP-9 (in vitro) than to MMP-1, and may therefore lack the musculoskeletal side effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70ee3ef4539380d926e3bf514bb287d7
https://doi.org/10.5414/cpp43282
https://doi.org/10.5414/cpp43282
Autor:
Ch. B. Lugt, P. A. M. Peeters, Polrat Wilairatana, Sornchai Looareesuwan, Frans A. E. Sollie, B. M. Schilizzi, James O. Peggins, B. Oosterhuis, Srivicha Krudsood
Publikováno v:
British Journal of Clinical Pharmacology. 53:492-500
Aims The antimalarial efficacy/pharmacodynamics and pharmacokinetics of intramuscular (i.m.) artemotil in Thai patients with acute uncomplicated falciparum malaria were studied to determine effective dose regimens and to compare these with the standa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58812b795f8e04ee845527130e449e87
https://doi.org/10.1046/j.1365-2125.2002.01590.x
https://doi.org/10.1046/j.1365-2125.2002.01590.x
Autor:
Sjoerd P. van Marle, Frans A. E. Sollie, Jochen Schmid, Heinz Switek, Aalt Verhagen, Jan H. G. Jonkman, W.J Tamminga, Dietrich Türck, Pierre Peeters, Joachim Stangier
Publikováno v:
The Journal of Clinical Pharmacology. 40:1312-1322
The study was conducted in healthy male volunteers to evaluate the absorption, metabolic pattern, and mode of elimination of telmisartan, a nonpeptide angiotensin II receptor antagonist. [14C]telmisartan was administered orally in solution as a singl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15b8d6073dee3364a1a059aa6073c85f
https://doi.org/10.1177/009127000004001202
https://doi.org/10.1177/009127000004001202
Autor:
Frans A. E. Sollie, B. Oosterhuis, Chung‐An P. F. Su, Jan H. G. Jonkman, Jan J. van Lier, Maarten G. C. Hendriks, Joachim Stangier
Publikováno v:
The Journal of Clinical Pharmacology. 40:1331-1337
The effects of multiple-dose telmisartan on the steady-state pharmacodynamics and pharmacokinetics of warfarin were assessed in 12 healthy young males in an open-label, single-period study conducted over 30 days. Subjects received loading doses of or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a82d46e0c009d5ad7e13a671ced964a5
https://doi.org/10.1177/009127000004001204
https://doi.org/10.1177/009127000004001204
The Effect of Telmisartan on the Steady‐State Pharmacokinetics of Digoxin in Healthy Male Volunteers
Autor:
Jan J. van Lier, B. Oosterhuis, Joachim Stangier, Frans A. E. Sollie, Chung‐An P. F. Su, Jan H. G. Jonkman, Maarten G. C. Hendriks
Publikováno v:
The Journal of Clinical Pharmacology. 40:1373-1379
A multiple-dose, open-label, two-period, crossover randomized study was conducted in 12 healthy male volunteers to investigate the effect of multiple-dose telmisartan on the steady-state pharmacokinetics of digoxin. On day 1 of a 7-day medication per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f4d6f7b4d2c85efb9c0bcbcb286890b
https://doi.org/10.1177/009127000004001209
https://doi.org/10.1177/009127000004001209
Autor:
John Allanson, Deborah A. Smith, Richard Peck, Nanco R. Hefting, Jan J. van Lier, Emma J. Seaber, Frans A. E. Sollie, Johan Wemer, Jan H. G. Jonkman
Publikováno v:
British Journal of Clinical Pharmacology. 46:433-439
Aims Zolmitriptan (Zomig (formerly 311C90)) is a novel 5-HT1B/1D receptor agonist developed for the acute oral treatment of migraine. A highly sensitive LCMS-MS assay has been developed which allows quantification of plasma concentrations of zolmitri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20e6deefe44da66cfe877a91e5a5f66b
https://doi.org/10.1046/j.1365-2125.1998.00809.x
https://doi.org/10.1046/j.1365-2125.1998.00809.x
Publikováno v:
The Journal of Clinical Pharmacology. 36:639-646
An open, randomized, three-period crossover study was conducted to compare the steady-state pharmacokinetics, pharmacodynamics, and tolerability of concomitant administration of BAY x 1005 and theophylline in 12 healthy volunteers. BAY x 1005 (250 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaefdebb8b7cae88c0d3ad909fdab199
https://doi.org/10.1002/j.1552-4604.1996.tb04229.x
https://doi.org/10.1002/j.1552-4604.1996.tb04229.x
Publikováno v:
Clinical pharmacology and therapeutics. 49(3)
During this open, two-period crossover study in eight healthy volunteers, 1200 mg anhydrous theophylline was administered as a two-stage infusion during 24 hours on day 6. During one of the 8-day periods, 300 mg caffeine, t.i.d., was administered ora
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb44e8ee5c728e61d6a16362c89003bc
https://pubmed.ncbi.nlm.nih.gov/2007319
https://pubmed.ncbi.nlm.nih.gov/2007319
Publikováno v:
Journal of Pharmacokinetics and Biopharmaceutics. 16:203-228
This investigation developed strategies along which the anticonvulsant effect of oxazepam in the rat could be pharmacokinetically modeled. After determination of the pharmacokinetics of oxazepam, which could be described with a two-compartment model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f07fec3922ed1cfa1e363fc010153a08
https://doi.org/10.1007/bf01062261
https://doi.org/10.1007/bf01062261